Targeting TNF: A therapeutic strategy for Alzheimer's disease

Drug Discovery Today

Volumn 19, Issue 11, 2014, Pages 1822-1827

  Cheng, Xin ^a   Shen, Yong ^a,b,c   Li, Rena ^b,d  

^a FUDAN UNIVERSITY   (China)

^b ROSKAMP INSTITUTE   (United States)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AUTOIMMUNE DISEASE; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; BRAIN NERVE CELL; BRAIN TISSUE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENETIC ANALYSIS; HUMAN; IMMUNITY; MULTICENTER STUDY (TOPIC); NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN PROCESSING; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; GENETICS; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910621430     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.029     Document Type: Review

References (61)

1. T. Shirai Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor Nature 313 1985 803 806
2. A. Marmenout Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor Eur. J. Biochem. 152 1985 515 522
3. M.M. de Jong The HLA class III subregion is responsible for an increased breast cancer risk Hum. Mol. Genet. 12 2003 2311 2319
4. M. Ghaderi Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer Hum. Immunol. 62 2001 1153 1158
5. C.V. Jongeneel Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes Proc. Natl. Acad. Sci. U. S. A. 88 1991 9717 9721
6. S. Nejentsev Non-class II HLA gene associated with type 1 diabetes maps to the 240-kb region near HLA-B Diabetes 49 2000 2217 2221
7. Y. Kawabata A second component of HLA-linked susceptibility to type 1 diabetes maps to class I region Ann. N. Y. Acad. Sci. 79 2006 278 284
8. E.A. Carswell An endotoxin-induced serum factor that causes necrosis of tumors Proc. Natl. Acad. Sci. U. S. A. 72 1975 3666 3670
9. L. Yang Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways J. Neurosci. 22 2002 3025 3032
10. Y. Shen Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line J. Biol. Chem. 272 1997 3550 3553
11. P. He Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice J. Cell Biol. 178 2007 829 841
12. H. Bruns Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans J. Clin. Invest. 119 2009 1167 1177
13. H. Li TNFalpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells J. Immunol. 181 2008 7131 7137
14. I.A. Ramshaw Cytokines and immunity to viral infections Immunol. Rev. 9 1997 119 135
15. D.H. Li Woodchuck lymphotoxin-alpha, -beta and tumor necrosis factor genes: structure, characterization and biological activity Gene 242 2000 295 305
16. B. Cheng Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis Neuron 12 1994 139 153
17. J.R. Patel, and G.J. Brewer Age-related changes to tumor necrosis factor receptors affect neuron survival in the presence of beta-amyloid J. Neurosci. Res. 86 2008 2303 2313
18. E.C. Beattie Control of synaptic strength by glial TNFalpha Science 295 2002 2282 2285
19. A.R. Ferguson Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane J. Neurosci. 28 2008 11391 11400
20. X. Cheng Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients J. Alzheimers Dis. 19 2010 621 630
21. L.F. Lue Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease Am. J. Pathol. 155 1999 853 862
22. Y. Shen Distinct destructive signal pathways of neuronal death in Alzheimer's disease Trends Mol. Med. 12 2006 574 579
23. R. Li Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death J. Neurosci. 24 2004 1760 1771
24. D.J. Selkoe Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav. Brain Res. 192 2008 106 113
25. S.S. Sisodia Alzheimer's disease: perspectives for the new millennium J. Clin. Invest. 104 1999 1169 1170
26. S.G. Younkin Evidence that Abeta 42 is the real culprit in Alzheimer's disease Ann. Neurol. 37 1995 287 288
27. J. Hardy The genetic causes of neurodegenerative diseases J. Alzheimers Dis. 3 2001 109 116
28. R. Li Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients Proc. Natl. Acad. Sci. U. S. A. 101 2004 3632 3637
29. M.A. Christensen Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1 Mol. Cell. Biol. 24 2004 865 874
30. Y. Li Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription FASEB J. 20 2006 285 292
31. E.M. Ramos Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease Arch. Neurol. 63 2006 1165 1169
32. D. Lio Tumor necrosis factor-alpha-308A/G polymorphism is associated with age at onset of Alzheimer's disease Mech. Ageing Dev. 127 2006 567 571
33. R.T. Perry Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls Am. J. Med. Genet. 105 2001 332 342
34. L. Bertram Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database Nat. Genet. 39 2007 17 23
35. A.G. Tristano Neurological adverse events associated with anti-tumor necrosis factor α treatment J. Neurol. 257 2010 1421 1431
36. F. Magro, and F. Protela Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies BioDrugs 24 Suppl 1 2010 3 14
37. J.Q. Shi Cognitive improvement with intrathecal administration of infliximab in a woman with Alzheimer's disease J. Am. Geriatr. Soc. 59 2011 1142 1144
38. S. Dhillon Etanercept: a review of its use in the management of rheumatoid arthritis Drugs 67 2007 1211 1241
39. D.L. Mann Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 2004 1594 1602
40. E.L. Tobinick, and H. Gross Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration J. Neuroinflammation 5 2008 2
41. E. Tobinick Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence CNS Drugs 23 2009 713 725
42. E.L. Tobinick, and H. Gross Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease BMC Neurol. 8 2008 27
43. E. Tobinick Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept CNS Drugs 26 12 2012 1051 1570
44. A.V. Muravyov Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment Clin. Hemorheol. Microcirc. 49 2011 431 439
45. A. Vakili Pentoxifylline attenuates TNF-α protein levels and brain edema following temporary focal cerebral ischemia in rats Brain Res. 1377 2011 119 125
46. M.C. Sha, and C.M. Callahan The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review Alzheimer Dis. Assoc. Disord. 17 2003 46 54
47. W.M. Kooloos Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease Drug Discov. Today 12 2007 125 131
48. G. La Rosa Inhibition of the nuclear factor-kappaB activation with pyrrolidine dithiocarbamate attenuating inflammation and oxidative stress after experimental spinal cord trauma in rats J. Neurosurg. Spine 1 2004 311 321
49. Q. Sun Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease J. Alzheimers Dis. 41 3 2014 877 886
50. J. Breitner ADAPT trial data Am. J. Med. 120 2007 e3
51. C.L. Meinert, and J.C. Breitner Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) Alzheimers Dement. 4 Suppl 1 2008 S7 S14
52. J.C. Breitner Extended results of the Alzheimer's disease anti-inflammatory prevention trial Alzheimers Dement. 7 2011 402 411
53. D. Tweedie A cellular model of inflammation for identifying TNFalpha synthesis inhibitors J. Neurosci. Methods 183 2009 182 187
54. S. Weggen A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 2001 212 216
55. D.R. Galasko Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals Alzheimer Dis. Assoc. Disord. 21 2007 292 299
56. G. Gasparini Thalidomide: an old sedative-hypnotic with anticancer activity? Curr. Opin. Investig. Drugs 2 2001 1302 1308
57. S. Fabro Toxicity and teratogenicity of optical isomers of thalidomide Nature 215 1967 296
58. J.P. Knisely A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118) Int. J. Radiat. Oncol. Biol. Phys. 71 2008 79 86
59. P. He Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease PLOS ONE 8 2013 e55091
60. H. Elçioʇlu Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats Biotech. Histochem. 88 2013 145 152
61. E. Abraham Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation J. Immunol. 170 2003 5644 5651